Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

Published:2023-07 Issue:10398 Volume:402 Page:291-303
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Agarwal Neeraj,Azad Arun A,Carles Joan,Fay Andre P,Matsubara Nobuaki,Heinrich Daniel,Szczylik Cezary,De Giorgi Ugo,Young Joung Jae,Fong Peter C C,Voog Eric,Jones Robert J,Shore Neal D,Dunshee Curtis,Zschäbitz Stefanie,Oldenburg Jan,Lin Xun,Healy Cynthia G,Di Santo Nicola,Zohren Fabian,Fizazi Karim

Publisher

Elsevier BV

Subject

General Medicine

Reference28 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Cancer statistics, 2023;Siegel;CA Cancer J Clin,2023

3. Prospective comprehensive genomic profiling of primary and metastatic prostate tumors;Chung;JCO Precis Oncol,2019

4. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency;Shen;Clin Cancer Res,2013

5. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy;Farmer;Nature,2005

Cited by 175 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Talazoparib enhances resection at DSBs and renders HR-proficient cancer cells susceptible to Polθ inhibition;Radiotherapy and Oncology;2024-11

2. Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives;Clinical Genitourinary Cancer;2024-10

3. Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment;Expert Review of Anticancer Therapy;2024-09-14

4. Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of 177Lu-PSMA-617 radioligand-therapy in prostate cancer;Clinical and Translational Oncology;2024-09-12

5. A panel‐based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration‐resistant prostate cancer;The Prostate;2024-09-09